Literature DB >> 9933646

Identification of the tissue inhibitor of metalloproteinases-2 (TIMP-2) binding site on the hemopexin carboxyl domain of human gelatinase A by site-directed mutagenesis. The hierarchical role in binding TIMP-2 of the unique cationic clusters of hemopexin modules III and IV.

C M Overall1, A E King, D K Sam, A D Ong, T T Lau, U M Wallon, Y A DeClerck, J Atherstone.   

Abstract

Cell surface activation of progelatinase A occurs in a quaternary complex with the tissue inhibitor of metalloproteinases-2 (TIMP-2) and two membrane-type matrix metalloproteinases. We have mutated the unique cationic clusters found in hemopexin modules III and IV of the carboxyl domain (C domain) of human gelatinase A to determine their role in binding TIMP-2. Twelve single, double, and triple site-directed mutations were produced that exhibited different TIMP-2 binding properties. Notably, single alanine substitutions at Lys547 and Lys617 reduced TIMP-2 binding by an order of magnitude from that of the recombinant wild-type C domain. Mutations that completely disrupted the C domain.TIMP-2 interaction were K558A/R561A, K610T/K617A, and K566A/K568A/K617A. A triple mutation, K566A/K568A/K575A, having TIMP-2 binding indistinguishable from the wild-type C domain (Kd 3.0 x 10(-8) M), showed that simple reduction of net positive charge does not reduce TIMP-2 affinity. Because the double mutation K566A/K568A also did not alter TIMP-2 binding, these data do not confirm previously reported chimera studies that indicated the importance of the triple lysine cluster at positions 566/567/568 in TIMP-2 binding. Nonetheless, a subtle role in TIMP-2 interaction for the 566/567/568-lysine triad is indicated from the enhanced reduction in TIMP-2 binding that occurs when mutations here were combined with K617A. Thus, these analyses indicate that the TIMP-2 binding surface lies at the junction of hemopexin modules III and IV on the peripheral rim of the gelatinase A C domain. This location implies that considerable molecular movement of the TIMP-2. C domain complex would be needed for the bound TIMP-2 to inhibit in cis the gelatinase A active site.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9933646     DOI: 10.1074/jbc.274.7.4421

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

Review 1.  Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention.

Authors:  W G Stetler-Stevenson
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).

Authors:  Xiaoping Xu; Margarita Mikhailova; Zhihua Chen; Sanjay Pal; Trista K Robichaud; Eileen M Lafer; Sam Baber; Bjorn Steffensen
Journal:  Matrix Biol       Date:  2011-08-04       Impact factor: 11.583

3.  The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases.

Authors:  Nadia Nour; Gaétan Mayer; John S Mort; Alexandre Salvas; Majambu Mbikay; Charlotte J Morrison; Christopher M Overall; Nabil G Seidah
Journal:  Mol Biol Cell       Date:  2005-08-31       Impact factor: 4.138

4.  TIMP-2 is required for efficient activation of proMMP-2 in vivo.

Authors:  Z Wang; R Juttermann; P D Soloway
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

5.  Tissue inhibitor of metalloproteinase-2 regulates matrix metalloproteinase-2-mediated endothelial barrier dysfunction and breast cancer cell transmigration through lung microvascular endothelial cells.

Authors:  Qiang Shen; Eugene S Lee; Robert L Pitts; Mack H Wu; Sarah Y Yuan
Journal:  Mol Cancer Res       Date:  2010-06-22       Impact factor: 5.852

6.  Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2.

Authors:  Ekaterina Morgunova; Ari Tuuttila; Ulrich Bergmann; Karl Tryggvason
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-28       Impact factor: 11.205

7.  Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp-4) gene.

Authors:  David A Young; Blaine W Phillips; Caroline Lundy; Robert K Nuttall; Aileen Hogan; Gilbert A Schultz; Kevin J Leco; Ian M Clark; Dylan R Edwards
Journal:  Biochem J       Date:  2002-05-15       Impact factor: 3.857

8.  A novel matrix metalloproteinase 2 (MMP2) terminal hemopexin domain mutation in a family with multicentric osteolysis with nodulosis and arthritis with cardiac defects.

Authors:  Beyhan Tuysuz; Rebecca Mosig; Gürkan Altun; Selim Sancak; Marc J Glucksman; John A Martignetti
Journal:  Eur J Hum Genet       Date:  2008-11-05       Impact factor: 4.246

9.  TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP.

Authors:  M Margarida Bernardo; Rafael Fridman
Journal:  Biochem J       Date:  2003-09-15       Impact factor: 3.857

10.  Bone sialoprotein does not interact with pro-gelatinase A (MMP-2) or mediate MMP-2 activation.

Authors:  Queena Hwang; Sela Cheifetz; Christopher M Overall; Christopher A McCulloch; Jaro Sodek
Journal:  BMC Cancer       Date:  2009-04-22       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.